Form D · Other Health Care
Pykus Therapeutics, Inc.
Cambridge, MA · CIK 0001840955
Offering snapshot reported Feb 5, 2021 · SEC filing
- Reported sold
- $2.49M Offering amount: $2.49M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2021 | Initial | $2,487,307 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-388583
Source: Form D, filed Feb 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carl Berke | Director |
| Richel Liu | Director |
| Sameer Sabir | Director |
| Michael Singer | Director |
| James A. Stefater | Executive |
| Thomas P. Stryjewski | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
One Mifflin Place, Suite 320
Cambridge, MA, 02138
Cambridge, MA, 02138